In vitro and in vivo studies carried out in human hepatocellular carcinoma cell lines and in a nude mouse model, respectively, showed that miR-320a could function as an antitumoral miRNA, whose binding to PBX3 affected the protein expression of cyclin-dependent kinase 2 (CDK2) and MMP-2 due to the reduction of the phosphorylation of ERK1/2. This evidence concerns the gene CDK2 and hepatocellular carcinoma.